New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19—A Large Postmortem and Clinical Analysis
暂无分享,去创建一个
B. Bein | Carsten Veit | A. de Weerth | D. Wichmann | S. Kluge | A. Heinemann | O. Detsch | K. Sydow | C. Weber | F. Heinrich | B. Ondruschka | K. Roedl | D. Jarczak | M. Bachmann | M. Bota | H. Goebels | Ulrich Schäfer | F. Ludwig | H. Paschen | P. Brand | U. Schäfer
[1] J. Halperin,et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.
[2] M. Christner,et al. SARS-CoV-2 Blood RNA Load Predicts Outcome in Critically Ill COVID-19 Patients , 2021, Open forum infectious diseases.
[3] M. Aepfelbacher,et al. Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases , 2021, Scientific Reports.
[4] Christopher M. Horvat,et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.
[5] P. T. Ten Eyck,et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial , 2021, Journal of Thrombosis and Haemostasis.
[6] H. Poor. Pulmonary Thrombosis and Thromboembolism in COVID-19 , 2021, Chest.
[7] Á. Avezum,et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.
[8] G. Lip,et al. Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID‐19 patients: A multicenter retrospective study , 2021, Journal of Thrombosis and Haemostasis.
[9] J. Hochman,et al. C-reactive protein and clinical outcomes in patients with COVID-19 , 2021, European heart journal.
[10] U. Janssens,et al. Recommendations on Inpatient Treatment of Patients with COVID-19. , 2021, Deutsches Arzteblatt international.
[11] C. Heinz,et al. Greater Fibrinolysis Resistance but No Greater Platelet Aggregation in Critically Ill COVID-19 Patients , 2021, Anesthesiology.
[12] A. Tsakris,et al. Association between upper respiratory tract viral load, comorbidities, disease severity and outcome of patients with SARS-CoV-2 infection , 2021, The Journal of infectious diseases.
[13] Shuo Yan,et al. High prevalence of occult thrombosis in cases of mild/moderate COVID-19 , 2020, International Journal of Infectious Diseases.
[14] D. Wichmann. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.
[15] H. Rohde,et al. Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients , 2020, Blood Advances.
[16] A. Belot,et al. Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure , 2020, Annals of Intensive Care.
[17] M. Aepfelbacher,et al. Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19 , 2020, American journal of respiratory and critical care medicine.
[18] B. Clary,et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis , 2020, EClinicalMedicine.
[19] D. Jiménez,et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.
[20] P. Enríquez,et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19 , 2020, Critical Care.
[21] B. Bein,et al. Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany , 2020, Australian Critical Care.
[22] A. Pazin-Filho,et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , 2020, Thrombosis Research.
[23] F. Ozturk,et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis , 2020, The American Journal of Emergency Medicine.
[24] T. Soumagne,et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients , 2020, European Respiratory Journal.
[25] J. Dillner,et al. Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[26] R. Busse,et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study , 2020, The Lancet Respiratory Medicine.
[27] Simon A. Jones,et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. , 2020, JAMA.
[28] Michael D Healy,et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality , 2020, Nature Communications.
[29] M. Aepfelbacher,et al. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.
[30] A. Lazo-Langner,et al. Thrombosis risk associated with COVID-19 infection. A scoping review , 2020, Thrombosis Research.
[31] J. Thachil,et al. Coagulopathy of Coronavirus Disease 2019 , 2020, Critical care medicine.
[32] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[33] M. Trauner,et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series , 2020, Annals of Internal Medicine.
[34] M. Revel,et al. Pulmonary embolism in patients with COVID-19 pneumonia , 2020, European Respiratory Journal.
[35] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[36] D. Gommers,et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.
[37] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[38] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[39] Malik Peiris,et al. Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.
[40] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[41] M. Humbert,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .
[42] M. Humbert,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) , 2019, European Respiratory Journal.
[43] Diana Altshuler,et al. Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient , 2018, Journal of intensive care medicine.
[44] G. Ferretti,et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis , 2015, Critical Care.